Goldman Sachs
SAGE

Goldman Sachs’s Sage Therapeutics SAGE Stock Holding History

Goldman Sachs’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,000
Closed -$340K – 6868
2021
Q4 		$340K Buy
+8,000
New +$335K ﹤0.01% 5604
2021
Q1 		– Sell
-11,100
Closed -$960K – 6310
2020
Q4 		$960K Buy
+11,100
New +$818K ﹤0.01% 4222
2020
Q2 		– Sell
-8,300
Closed -$238K – 5449
2020
Q1 		$238K Sell
8,300
-16,800
-67% -$973K ﹤0.01% 4623
2019
Q4 		$1.81M Buy
+25,100
New +$3.09M ﹤0.01% 3716
2017
Q4 		– Sell
-40,100
Closed -$2.5M – 6607
2017
Q3 		$2.5M Sell
40,100
-212,400
-84% -$16.7M ﹤0.01% 3783
2017
Q2 		$20.1M Buy
+252,500
New +$18.3M 0.01% 1927
2016
Q3 		– Sell
-140,000
Closed -$4.22M – 7159
2016
Q2 		$4.22M Buy
+140,000
New +$4.67M ﹤0.01% 2998
2016
Q1 		– Sell
-50,000
Closed -$2.92M – 7292
2015
Q4 		$2.92M Sell
50,000
-48,800
-49% -$2.42M ﹤0.01% 3305
2015
Q3 		$4.18M Buy
+98,800
New +$6.09M ﹤0.01% 3047

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's SAGE Position: Q3 2025 in Review

Goldman Sachs sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 519,107 shares — an estimated $4.73M sold.

Goldman Sachs first reported a position in SAGE in Q3 2014 and held it in 44 quarters. The position peaked at $66.2M in Q2 2018. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Goldman Sachs reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 519,107 Sage Therapeutics shares in Q3 2025, an estimated $4.73M.
  • Goldman Sachs first reported a position in Sage Therapeutics in Q3 2014 and held it in 44 quarters.
  • Goldman Sachs's Sage Therapeutics position peaked at $66.2M in Q2 2018.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.